久久精品sp欧美,激情综合亚洲二区,制服丝袜_1页_爱中色综合,亚洲中文字幕宗合网

    1. <sup id="p9mmb"></sup>
      1. 豪森藥業(yè)
        • Overview
        • 1995 Initial establishment
          A principal subsidiary of Hansoh Pharma (03692.HK)
          7
          Launched innovative drugs
          Top 100
          Pharmaceutical companies worldwide
          Top 3
          China's best Industrial enterprises in pharmaceutical R&D pipeline

        Therapy Areas

        • Anti-tumor
          Anti-tumor
          Anti-tumor
          Anti-tumor
          Anti-tumor
          Anti-tumor
          We focus on the develoment of new drugs in the field of common and hostile cancers.Our innovative medicine programs in clinical trials include HS-20106 injection, HS-20105 injection, HS-20117 injection, HS-10516 capsules, HS-10382 tablets, HS-10370 tablets, HS-10502 tablets, HS-10365 capsules, HS-20089 injection, HS-20093 injection, HS-10352 tablets, HS-10241 tablets, etc.
          More +
        • Anti-infectives
          Anti-infectives
          Anti-infectives
          Anti-infectives
          Anti-infectives
          Anti-infectives
          We focus on the development of new drugs in the fields of antiviral, anti-complex bacterial infection and anti-fungal infection. Our innovative medicine programs in clinical trials includeCitric Acid Erythorbate tablets, etc.
          More +
        • CNS Diseases
          CNS Diseases
          CNS Diseases
          CNS Diseases
          CNS Diseases
          CNS Diseases
          We focus on the development of new drugs in the fields of psychiatric and neurological disorders.Our innovative medicine programs in clinical trials include HS-10380 tablets, HS-10506 tablets, HS-10353 capsules, HS-10509 tablets, etc.
          More +
        • Metabolic Diseases
          Metabolic Diseases
          Metabolic Diseases
          Metabolic Diseases
          Metabolic Diseases
          Metabolic Diseases
          We focus on the development of new drugs in the field of metabolic diseases such as diabetes and obesity. Our innovative medicine programs in clinical trials include HS-10511 tablets, HS-20094 injection, HS-10384 tablets, HS-10518 capsules, HS-10390 tablets, HS-10501 tablets, and HS-10398 capsules, etc.
          More +
        • Autoimmune Diseases
          Autoimmune Diseases
          Autoimmune Diseases
          Autoimmune Diseases
          Autoimmune Diseases
          Autoimmune Diseases
          We focus on the development of new drugs in the field of autoimmune diseases. Our innovative medicine programs in clinical trials includeHS-10374 tablets etc.
          More +
        R&D
        Innovation
        Jiangsu Hansoh Pharma Research Institute
        Jiangsu Hansoh Pharma Research Institute
        More
        Jiangsu Hansoh Pharma Administrative R&D Center
        Jiangsu Hansoh Pharma Administrative R&D Center
        More
        • Substantial investment on R&D
          In 2024, R&D expenditure was RMB2,702 million, and accounted for 22.0% of the revenue.
        • Competitive R&D pipeline
          More than 60 clinical trials of innovative drug candidates being investigated, covering 40 innovative drug candidates.
        • Highly efficient capability to discover innovative drugs
          The R&D pipeline covers peptides , small molecules, biologics, ADC drugs, siRNAs, and more.
        A broader world, let's discover together
        Join Hansoh Pharma +
        Work with us
        We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!
        Join Hansoh Pharma +